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Abstract—Gas-filled microbubbles have the potential to become 
a unique intravascular MR contrast agent due to their magnetic 
susceptibility effect, biocompatibility and localized manipulation 
via ultrasound cavitation. However, in vivo demonstration of 
microbubble susceptibility effect is limited so far and 
microbubble susceptibility effect is relatively weak when 
compared with other intravascular MR susceptibility contrast 
agents. In this study, two types of microbubbles, custom-made 
albumin-coated microbubbles (AMBs) and a commercially 
available lipid-based clinical ultrasound contrast agent 
(SonoVue®), were investigated with in vivo dynamic brain and 
liver MRI in Sprague-Dawley rats at 7 Tesla. Transverse 
relaxation rate enhancements (ΔR2*) maps were computed for 
brain and liver, yielding results similar to those obtained with a 
common MR blood pool contrast agent. These results indicate 
that gas-filled microbubbles can serve as an intravascular MR 
contrast agent at high field. Enhancement of microbubble 
susceptibility effect by entrapping monocrystalline iron oxide 
nanoparticles (MIONs) into microbubbles was also investigated 
at 7 T in vitro. This is the first experimental demonstration of 
microbubble susceptibility enhancement for MRI application. 
This study indicates that gas-filled microbubble susceptibility 
effect can be substantially increased using iron oxides 
nanoparticles. With such approach, microbubbles can 
potentially be visualized with higher sensitivity and lower 
concentrations by MRI. Such capability has the potential to lead 
to real-time MRI guidance in various microbubble-based drug 
delivery and therapeutic applications. 
I. INTRODUCTION 
as-filled microbubles can potentially be used as an 
intravascular MR susceptibility contrast agent in vivo 
due to the induction of large local magnetic susceptibility 
difference by the gas-liquid interface. Moreover, 
microbubbles can be locally cavitated and destroyed by 
focused ultrasound [1], hence the MR signals can be 
temporally and spatially manipulated because microbubble 
disappearances will diminish the susceptibility effect. 
Recently, microbubbles have been employed in therapeutic 
applications due to their unique cavitation [2] and 
sonoporation [3] properties. Site-specific release of 
incorporated drugs or genes inside microbubbles can be 
achieved with local microbubble cavitation by spatially 
focused ultrasound. Microbubble-mediated sonoporation can 
dramatically increase cell permeability and intracellular 
uptake [4], with substantial increase in gene transfection 
efficiency and therapeutic effectiveness being demonstrated. 
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Furthermore, several therapeutic interventions, like 
sonothrombolysis [5], transient opening of blood-brain barrier 
potentially for delivery of both low and high molecular weight 
therapeutic compounds [6] and enhancing the high intensity 
focused ultrasound therapy by increasing the local heating rate 
[7] have been demonstrated. 
Early experiment with Albunex®, an ultrasound contrast 
agent consisting of air-filled microbubbles with human 
albumin shell, illustrated the potential of air-filled 
microbubbles as an MR susceptibility contrast agent [8]. 
Feasibility of microbubbles as an MR pressure sensor, based 
on the susceptibility change caused by pressure-induced 
microbubble size change, has been explored through 
theoretical [9] and phantom [10] studies. The first in vivo 
investigation of susceptibility contrast induced by 
microbubbles was reported by our group previously using 
Optison®, microbubbles of human albumin shells with 
perfluorocarbon as core gas, at 7 T in rat liver [11]. R2* 
dependency on microbubble volume fraction was also 
reported for Levovist®, air-filled microbubbles with palmitic 
acid shells, through an in vitro phantom study at 1.5 T [12]. 
Magnetic susceptibility enhancement induced by gas-liquid 
interface was demonstrated recently by simulations and MR 
experiments using air-filled cylinders in water [13], 
consolidating the feasibility of gas-filled microbubbles as an 
MR susceptibility contrast agent. However, in vivo 
demonstration is limited so far and microbubble susceptibility 
effect is still relatively weak when compared with other 
intravascular MR susceptibility contrast agents [11, 14]. 
In this study, we aim to further investigate and demonstrate the 
in vivo MR susceptibility effect induced by both custom-made 
albumin-coated microbubbles and commercially available 
lipid-based microbubbles in rat brain and liver at 7 T using 
dynamic susceptibility weighted MRI, and experimentally 
demonstrate that microbubble R2* can be enhanced by 
embedded or entrapping monocrystalline iron oxide 
nanoparticles (MIONs) [15] into microbubble shells. 
II. METHODOLOGY 
All MRI experiments were performed on a 7 T MRI scanner 
with a maximum gradient of 360 mT/m (70/16 PharmaScan, 
Bruker Biospin GmbH, Germany). All animal experiments 
were approved by the local institutional animal ethics 
committee. 
A. Microbubble Preparation 
A commercially available clinical ultrasound contrast agent 
(SonoVue®, Bracco, Milan, Italy), was used in this study. 
SonoVue® microbubbles consist of sulphur hexafluoride gas 
stabilized in an aqueous dispersion by a phospholipid 
monolayer. Air-filled custom-made albumin-coated 
microbubbles (AMBs) were produced by sonication as 
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previously described [16]. AMBs with MIONs embedded in 
shells were synthesized [17]. Polymeric microbubbles (PMBs) 
with MIONs incorporated or entrapped in shells were 
produced by adapting a double emulsion procedure [17]. 
MION-free PMBs were synthesized with the same procedure 
except using deionized water instead of the MION solution. 
B. Animal Preparation and Microbubble Administration 
Ten normal adult Sprague-Dawley rats (~250-350 g) were 
used. Each rat was anesthetized with intraperitoneal injection 
of ketamine (100 mg/kg) and xylazine (10 mg/kg). Femoral 
vein catheterization was performed. During imaging, animals 
were anesthetized with isoflurane/air using 1.0-1.5% via a 
nose cone with respiratory monitoring. Microbubbles were 
first warmed slowly to room temperature. Resuspension was 
performed until a homogenous milky-white suspension 
formed. For each imaging session, 0.2 mL of microbubble 
suspension (of ~4% volume fraction for AMBs and ~3.5% 
volume fraction for SonoVue®) was slowly injected (over 
~10 s) into femoral vein at a rate of 1.2 mL/min to avoid 
possible microbubble destruction due to high pressure and 
shear stress. 
C. Susceptibility Contrast Imaging of Rat Brain 
In vivo brain imaging was performed in rats (N = 5) using a 
38-mm quadrature resonator. Anatomical images were 
acquired with two-dimensional (2D) fast low-angle shot 
(FLASH) sequence. Dynamic susceptibility weighted MRI 
was performed with single-shot GE echo-planner imaging 
(GE-EPI) sequence using TR = 1000 ms, TE = 30 ms, flip 
angle = 90º, acquisition matrix = 96 × 96, spatial resolution = 
0.3 × 0.3 × 0.7 mm3 and NEX = 1. Microbubble suspension 
was injected about 5 min after the start of dynamic imaging. A 
minimum lapse of 10 min was used to ensure sufficient 
clearance of the microbubbles before the next injection. The 
susceptibility effect of microbubbles was compared with that 
of MIONs [18-20] in brain by a single dose of 0.6 mg Fe/kg 
injection using identical injection protocol and imaging 
sequence. 
D. Susceptibility Contrast Imaging of Rat Liver 
Liver imaging was performed in rats (N = 5) using a 60-mm 
quadrature resonator. Dynamic MRI was then performed with 
respiratory-gated of similar protocol as brain imaging, except 
that TE = 10 ms, acquisition matrix = 64 × 64, spatial 
resolution = 0.78 × 0.78 × 2.0 mm3 and NEX = 1. The 
susceptibility effect of microbubbles was also compared with 
that of MIONs in liver by a single dose of 0.6 mg Fe/kg 
injection. 
E. In vivo Data Analysis 
GE-EPI images were first co-registered using AIR5.2.5 [21]. 
Apparent transverse relaxation rate enhancement (ΔR2*) maps 
were computed on a pixel-by-pixel basis as ΔR2* = ln 
(Spre/Savg-post)/TE [22]. Assuming that ΔR2* is proportional to 
microbubble concentration C(t) at time t, C(t) can be estimated 
as C(t) = k ln {Spre/S(t)}/TE + CB, where S(t) is the image 
intensity at time t, k a proportionality constant, and CB a 
constant residue to account for any postinjection baseline [11]. 
Given the relatively long injection time and the limited 
lifetime of microbubbles in vivo, C(t) were approximately 
modeled with a gamma-variate function by curve fitting [23]. 
Full width at half maximum (FWHM) and time-to-peak were 
then measured from the fitted C(t) time courses. 
F. Ultrasound Demonstration 
Ultrasound imaging (Sonix RP, Ultrasonix) was preformed in 
rat livers (N = 2) using SonoVue® to demonstrate 
microbubble induced contrast change for comparison. 
G. Measurement of ΔR2* of MION-free and 
MION-entrapped AMB and PMB Suspensions 
Microbubble phantom study was performed with 38-mm 
quadrature resonator. AMBs were diluted from a well-mixed 
microbubble suspension to 4% volume fraction with the 
addition of saline, while PMBs of 5 % volume farction were 
prepared by addition of saline. The microbubbles were then 
placed in separate 2-mL cylindrical phantom tubes. Each 
phantom tube was slowly warmed to room temperature and 
gently mixed for 2 min outside the magnet prior to MR 
measurements. To ensure uniform suspension of 
microbubbles, the phantom was then continuously stirred by 
rotation inside the magnet. It was then arrested in horizontal 
position immediately before the start of MR acquisition 
sequence.  
ΔR2* was measured by acquiring multi-echo GE signals 
continuously without phase encoding for 2 min from an axial 
1-mm slice at middle of the phantom as previously described 
[17]. Microbubble induced ∆R2* was then calculated as the 
difference between R2* in the initial state and that in the final 
state. To demonstrate that MION were embedded and 
entrapped, microbubble-free suspending solutions R2* was 
measured before and after cavitation (using ultrasound of 
frequency 40 kHz) with multiple gradient echo sequences. 
III. RESULTS AND DISCUSSIONS 
A. Characterization of AMBs and SonoVue® 
The light micrographs of a representative batch of AMBs and 
SonoVue® microbubbles were depicted in Figs. 1(a) and (b), 
respectively. The estimated size distribution was from 1 to 23 
µm (with 9.21 µm mean diameter) for AMBs and 1 to 10 µm 
(with 2.95 µm mean diameter) for SonoVue®. Fig. 2 shows 
the dependency of ∆R2* on microbubble volume fractions in 
AMBs and SonoVue® microbubble suspension phantoms. An 
approximately linear relationship was observed. The 
relaxivities estimated from the fitted slopes were 58.52 (s · 
volume fraction)-1 and 52.94 (s · volume fraction)-1 for AMBs 
and SonoVue®, respectively, consistent with the microbubble 
susceptibility effect in a theoretical study [9]. 
 
 Fig. 1. Representative light micrograph (magnification = 20x) of (a) 
AMB and (b) SonoVue® microbubble suspensions.  
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B. In vivo Rat Brain Imaging 
Fig. 3 illustrates the rat brain images typically observed during 
AMBs injection. Note that the microbubbles induced ∆R2* 
maps were observed to be similar to those caused by 
intravascular MION. Similar results were observed for 
SonoVue® injection. Table 1 shows the in vivo measurements 
of ∆R2*, FWHM and time-to-peak of AMBs and SonoVue®, 
as well as ∆R2* and time-to-peak of MION in cortex area 
among all rats studied. Time-to-peak of microbubbles was 
found to be longer than that of MION. This is largely expected 
as microbubbles, with size comparable to that of red blood 
cells, flow slower than blood plasma while MION 
nanoparticles flow together with plasma. In few of the rats 
studied (1 out of 5 in brain imaging), the T2*-weighted signals 
after microbubble injection did not return to the preinjection 
baseline, this may be caused by microbubble trapping in local 
tissue vasculature. 
 
 
 
 
 
 
 
 
 
C. In vivo Rat Liver Imaging 
Fig. 4 illustrates the rat liver images typically observed during 
AMBs and SonoVue® injection. The signal time course 
during SonoVue® injection captured by ultrasound imaging 
was overlaid in grey for comparison. Note that the ultrasound 
signal was enhanced by microbubbles. Similar signal 
recovering patterns were observed, showing comparable 
lifetime of SonoVue® in vivo. Table 1 shows the measured 
∆R2*, FWHM and time-to-peak of AMBs and SonoVue®, as 
well as ∆R2* and time-to-peak of MION in liver. Time-to-peak 
of microbubbles was also found to be longer than that of 
MION. In few of the rats studied (2 out of 5 in liver imaging), 
the T2*-weighted signals after microbubble injection did not 
return to the preinjection baseline, possible uptake of intact 
microbubbles by Kupffer cells in liver may also contribute to 
such observation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ΔR2* (s-1) FWHM (s) Time-to-peak (s) 
Brain    
AMBs 2.49 ± 1.00 114 ± 39 57 ± 20 
SonoVue® 2.41 ± 1.18 86 ± 16 48 ± 12 
MIONs 1.98 ± 0.36 N.A. 24 ± 2 
    
Liver    
AMBs 40.89 ± 22.08 119 ± 68 60 ± 24 
SonoVue® 45.78 ± 34.22 95 ± 41 58 ± 28 
MIONs 55.84 ± 21.75 N.A. 39 ± 14 
D. Measurement of ΔR2* of MION-free and 
MION-entrapped PMB Suspensions 
Fig. 5 shows the individual microbubble-induced ∆R2* values 
in six batches of PMBs at 5% volume fraction and one batch of 
AMBs at 4 % volume fraction with and without MIONs, each 
measured with six repeated measurements. Suspending 
solution R2* for AMBs without and with MIONs after 
cavitation were found to be increased by 1.41 s-1 and 23.91 s-1 
respectively. Similarly, suspending solution R2* for PMBs 
Fig. 3. Typical images from a rat brain during AMBs injection: (a) 
anatomical image; (b) preinjection GE-EPI T2*-weighted image; (c) 
postinjection GE-EPI T2*-weighted image with the maximum 
susceptibility contrast; (d) T2*-weighted signal time courses in 
different ROIs during AMBs injection; (e) ∆R2* map computed from 
AMB data; and (f) ∆R2* map obtained using intravascular contrast 
agent MIONs at 0.6 mg Fe/kg. Three ROIs used for time course 
measurements are shown in (b) and gamma-variate fitted data shown 
in sold lines. 
Fig. 4. Corresponding images from the same rat liver during microbubble 
injections: (a) anatomical image, (b) preinjection GE-EPI T2*-weighted 
image for AMBs and (c) postinjection GE-EPI T2*-weighted image with 
the maximum susceptibility contrast for AMB. T2*-weighted signal time 
courses in different liver regions during (d) AMB and (e) SonoVue® 
injection in the same rat. ∆R2* maps for (f) AMBs, (g) SonoVue® and (h) 
0.6 mg Fe/kg MIONs. Two ROIs for time course measurement, a 
homogenous liver region (LV) and the region covering inferior vena cava 
(IVC), are shown in (b). Gamma-variate fitted data are shown in sold 
lines. Ultrasound measurement (grey line) was overlaid in (e) for 
comparison.
Table 1. In vivo measurements of relaxation rate enhancement (∆R2*), full 
width at half maximum (FWHM) and time-to-peak of the concentration 
time courses for AMBs, SonoVue® and MIONs in rat brain cortex (mean 
± standard deviation, N = 5) and liver (mean ± standard deviation, N = 5).
Fig. 2. Measured ΔR2* of (a) AMBs and (b) SonoVue® microbubble 
suspensions versus microbubble volume fractions. The error bars 
represent standard deviation. 
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without and with MIONs after cavitation were found to be 
increased by 0.3 ± 0.4 s-1 and 55 ± 9 s-1 respectively. These 
substantial differences for microbubbles with MIONs 
demonstrate that there were more MIONs in the suspending 
solution after cavitation; suggesting that embedded and 
entrapped MION were released into suspending solution after 
the microbubble cavitation. Transmission electron microscopy 
was done on AMBs with MION and depicted in Fig. 6. 
MIONs as dark dots (red arrows) were observed on the shells 
of AMB, validating MIONs were embedded onto shells of 
AMBs. Nevertheless, small amount of free MIONs were also 
observed in suspending solution (green arrow). Larger iron 
oxide nanoparticles like superparamagnetic iron oxide 
nanoparticles (SPIOs) or FePt@Fe2O3 yolk−shell 
nanoparticles [24], may be used to further enhance the 
microbubble magnetic susceptibility effect [25]. 
       
 
 
IV. CONCLUSIONS 
In this study, we investigated the feasibility of gas-filled 
microbubbles as an intravascular MR susceptibility contrast 
agent in vivo at 7 T.  Considerable susceptibility induced 
changes were observed and characterized in rat brain and liver 
using the custom-made albumin-coated microbubbles and a 
commercially available clinical ultrasound microbubble 
contrast agent. The results indicate that microbubbles can 
serve as a unique intravascular MR contrast agent at high field. 
We also demonstrated, for the first time, that embedding or 
entrapping iron oxide nanoparticles in microbubbles is 
feasible. With such approach, microbubble susceptibility can 
be significantly enhanced, so that microbubbles can be 
monitored with high sensitivity and low concentrations under 
MRI. Such capability has the potential to lead to real-time 
MRI guidance in various microbubble-based drug delivery 
and therapeutic applications. 
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Fig. 5. Microbubble induced ∆R2* of 
different microbubbles. The error bars 
represent one standard deviation 
Fig. 6. Transmission electron 
microsgraph shows MIONs were 
embedded onto shells of AMBs.
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